Cubist Systematic Strategies, LLC Inhibrx, Inc. Transaction History

Cubist Systematic Strategies, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$18.45 - $27.14 $352,487 - $518,509	19,105 Added 42.62%	63,931 $1.21 Million
Q4 2022 Feb 14, 2023	SELL	$20.18 - $33.33 $645,739 - $1.07 Million	-31,999 Reduced 41.65%	44,826 $1.1 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $190,247 - $406,289	16,429 Added 27.2%	76,825 $1.38 Million
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $391,033 - $1.16 Million	45,896 Added 316.52%	60,396 $685,000
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $83,538 - $181,356	4,200 Added 40.78%	14,500 $323,000
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $275,525 - $474,006	10,300 New	10,300 $450,000

51.7K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $606M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.